替吉奥联合奥沙利铂治疗晚期结直肠癌的临床观察_West China Medical Journal

Authors：

 于瑞莲 , 陈琳

四川省医学科学院·四川省人民医院肿瘤科（成都，610072）;

Corresponding author：

Keywords：

替吉奥胶囊; 奥沙利铂; 晚期结直肠癌; 毒副作用

DOI：

10.7507/1002-0179.20140091

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

目的评价替吉奥胶囊联合奥沙利铂治疗晚期结直肠癌患者的近期疗效和不良反应。方法回顾性分析2010年8月－2012年12月64例晚期结直肠癌患者资料，32例采用替吉奥联合奥沙利铂（L-OHP）方案化学疗法（替吉奥组），32例采用氟尿嘧啶联合奥沙利铂（FOLFOX）方案化学疗法（氟尿嘧啶组），2周期后评价两组疗效及不良反应。结果替吉奥组和氟尿嘧啶组总有效率分别为50.0%和46.9%，两组差异无统计学意义（χ²=0.063，P=0.802）；两组骨髓抑制及胃肠道反应发生率相近，但静脉炎的发生率替吉奥组明显低于氟尿嘧啶组（0.0%、9.4%，P＜0.05）。结论替吉奥胶囊联合奥沙利铂治疗晚期结直肠癌，近期疗效较好，不良反应较轻。

Citation： 于瑞莲, 陈琳. 替吉奥联合奥沙利铂治疗晚期结直肠癌的临床观察. West China Medical Journal, 2014, 29(2): 300-302. doi: 10.7507/1002-0179.20140091 Copy

1.	Chemotherapy of metastatic colorectal cancer[J].Prescrire Int,2010,19(109):219-224.
2.	Cai X,Cao W,Ding H,et al.Analysis of UGT1A1^*28 genotype and SN-38 pharmacokinetics for irinotecan-based chemotherapy in patients with advanced colorectal cancer:results from a multicenter,retrospective study in Shanghai[J].J Cancer Res Clin Oncol,2013,139(9):1579-1589.
3.	杨学宁,吴一龙.实体瘤治疗疗效评价标准RECIST[J].循证医学,2004,4(2):85-111.
4.	周际昌.实用肿瘤内科学[M].2版.北京:人民卫生出版社,2005:606.
5.	Shirasaka T,Nakano K,Takechi T,et al.Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats[J].Cancer Res,1993,56(11):2602-2606.
6.	Tatsumi K,Fukushima M,Shirasaka T,et al.Inhibitory effects of pyrimidine,barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts[J].Jpn J Cancer Res,1987,78(8):748-755.
7.	Shirasaka T,Shimamoto Y,Fukushima M.Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats[J].Cancer Res,1993,53(17):4004-4009.
8.	Van den Brande J,Schöffski P,Schellens JH,et al.EORTC Early Clinical Studies Group early phase Ⅱ trial of S-1 in patients with advanced or metastatic colorectal cancer[J].Br J Cancer,2003,88(5):648-653.
9.	Zang DY,Lee BH,Park HC,et al.Phase Ⅱ study with oxaliplatin and S-1 for patients with metastatic colorectal cancer[J].Ann Oncol,2009,20(5):892-896.
10.	Hong YS,Park YS,Lim HY,et al.S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer:a randomised,non-inferiority phase 3 trial[J].Lancet Oncol,2012,13(11):1125-1132.

1. Chemotherapy of metastatic colorectal cancer[J].Prescrire Int,2010,19(109):219-224.
2. Cai X,Cao W,Ding H,et al.Analysis of UGT1A1^*28 genotype and SN-38 pharmacokinetics for irinotecan-based chemotherapy in patients with advanced colorectal cancer:results from a multicenter,retrospective study in Shanghai[J].J Cancer Res Clin Oncol,2013,139(9):1579-1589.
3. 杨学宁,吴一龙.实体瘤治疗疗效评价标准RECIST[J].循证医学,2004,4(2):85-111.
4. 周际昌.实用肿瘤内科学[M].2版.北京:人民卫生出版社,2005:606.
5. Shirasaka T,Nakano K,Takechi T,et al.Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats[J].Cancer Res,1993,56(11):2602-2606.
6. Tatsumi K,Fukushima M,Shirasaka T,et al.Inhibitory effects of pyrimidine,barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts[J].Jpn J Cancer Res,1987,78(8):748-755.
7. Shirasaka T,Shimamoto Y,Fukushima M.Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats[J].Cancer Res,1993,53(17):4004-4009.
8. Van den Brande J,Schöffski P,Schellens JH,et al.EORTC Early Clinical Studies Group early phase Ⅱ trial of S-1 in patients with advanced or metastatic colorectal cancer[J].Br J Cancer,2003,88(5):648-653.
9. Zang DY,Lee BH,Park HC,et al.Phase Ⅱ study with oxaliplatin and S-1 for patients with metastatic colorectal cancer[J].Ann Oncol,2009,20(5):892-896.
10. Hong YS,Park YS,Lim HY,et al.S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer:a randomised,non-inferiority phase 3 trial[J].Lancet Oncol,2012,13(11):1125-1132.

Previous Article
腹腔镜结直肠癌根治术在合并慢性阻塞性肺疾病患者中的可行性研究
Next Article
麝香保心丸治疗老年慢性充血性心力衰竭的疗效观察

West China Medical Journal

替吉奥联合奥沙利铂治疗晚期结直肠癌的临床观察

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content